FDA Clears Self-Administered Lupus Therapy - Top_Thought_Leaders - MDSpire

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

  • By

  • Kathryn Wighton

  • April 28, 2026

  • 2 min

Share

Top Thought Leaders in Rheumatology

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Clears Self-Administered Lupus Therapy

  • by Kathryn Wighton

  • April 28, 2026

Related Content

Rehab May Improve Function in AS

Supervised rehabilitation and exercise-based therapies may improve function, pain, and bone health in ankylosing spondylitis, according to a new review.

Lung Disease Complicates RA Care

Patients with chronic lung disease had numerically lower remission rates and substantially more serious adverse events in a 5-year Japanese registry study of late-onset rheumatoid arthritis.

Antibiotic Falls Short in Disc-Related Back Pain

A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.